Cargando…

Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis

BACKGROUND: Despite improvements in treatment success rates for tuberculosis (TB), current six-month regimen duration remains a challenge for many National TB Programmes, health systems, and patients. There is increasing investment in the development of shortened regimens with a number of candidates...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomez, G. B., Dowdy, D. W., Bastos, M. L., Zwerling, A., Sweeney, S., Foster, N., Trajman, A., Islam, M. A., Kapiga, S., Sinanovic, E., Knight, G. M., White, R. G., Wells, W. A., Cobelens, F. G., Vassall, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131398/ https://www.ncbi.nlm.nih.gov/pubmed/27905897 http://dx.doi.org/10.1186/s12879-016-2064-3

Ejemplares similares

The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa
por: Knight, Gwenan M., et al.
Publicado: (2015)

Shortened first-line TB treatment in Brazil: potential cost savings for patients and health services
por: Trajman, Anete, et al.
Publicado: (2016)

Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling
por: Dowdy, D. W., et al.
Publicado: (2014)

Modeling of Novel Diagnostic Strategies for Active Tuberculosis – A Systematic Review: Current Practices and Recommendations
por: Zwerling, Alice, et al.
Publicado: (2014)

Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation
por: Vassall, Anna, et al.
Publicado: (2017)

Tuberculosis screening costs and cost-effectiveness in high-risk groups: a systematic review
por: Alsdurf, H., et al.
Publicado: (2021)

Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study
por: Verguet, Stéphane, et al.
Publicado: (2017)

A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology
por: Cunnama, Lucy, et al.
Publicado: (2020)

Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis
por: Shrestha, Sourya, et al.
Publicado: (2014)

Correction to: A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology
por: Cunnama, Lucy, et al.
Publicado: (2020)

A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis
por: Fofana, Mariam O., et al.
Publicado: (2017)

Mathematical Modelling and Tuberculosis: Advances in Diagnostics and Novel Therapies
por: Zwerling, Alice, et al.
Publicado: (2015)

MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis
por: Kendall, Emily A., et al.
Publicado: (2017)

Using Top‐down and Bottom‐up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at Scale
por: Cunnama, Lucy, et al.
Publicado: (2016)

Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support
por: Nsengiyumva, Ntwali Placide, et al.
Publicado: (2018)

Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis
por: Mullie, Guillaume A., et al.
Publicado: (2017)

Examining Approaches to Estimate the Prevalence of Catastrophic Costs Due to Tuberculosis from Small-Scale Studies in South Africa
por: Sweeney, Sedona, et al.
Publicado: (2020)

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
por: Sweeney, Sedona, et al.
Publicado: (2022)

Strengthening health systems to improve the value of tuberculosis diagnostics in South Africa: A cost and cost-effectiveness analysis
por: Foster, Nicola, et al.
Publicado: (2021)

Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees
por: Ilaiwy, Ghassan, et al.
Publicado: (2021)

Costs and Consequences of Using Interferon-γ Release Assays for the Diagnosis of Active Tuberculosis in India
por: Little, Kristen M., et al.
Publicado: (2015)

Financing and cost-effectiveness analysis of public-private partnerships: provision of tuberculosis treatment in South Africa
por: Sinanovic, Edina, et al.
Publicado: (2006)

Cost of TB prevention and treatment in the Philippines in 2017
por: Capeding, T. P. J., et al.
Publicado: (2022)

Scaling up investigation and treatment of household contacts of tuberculosis patients in Brazil: a cost-effectiveness and budget impact analysis
por: Bastos, Mayara Lisboa, et al.
Publicado: (2022)

Costs of TB services in India
por: Chatterjee, S., et al.
Publicado: (2021)

Modelling the cost-effectiveness of a new infant vaccine to prevent tuberculosis disease in children in South Africa
por: Channing, Liezl, et al.
Publicado: (2014)

Population-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis
por: Fofana, Mariam O., et al.
Publicado: (2014)

Patients' Costs and Cost-Effectiveness of Tuberculosis Treatment in DOTS and Non-DOTS Facilities in Rio de Janeiro, Brazil
por: Steffen, Ricardo, et al.
Publicado: (2010)

Costs and cost-effectiveness of a comprehensive tuberculosis case finding strategy in Zambia
por: Jo, Youngji, et al.
Publicado: (2021)

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
por: Lai, Wendy A., et al.
Publicado: (2022)

How can mathematical models advance tuberculosis control in high HIV prevalence settings?
por: Houben, R. M. G. J., et al.
Publicado: (2014)

Cost-effectiveness of newer technologies for the diagnosis of Mycobacterium tuberculosis infection in Brazilian people living with HIV
por: Steffen, Ricardo E., et al.
Publicado: (2020)

Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review
por: Laurence, Yoko V., et al.
Publicado: (2015)

Cost of three models of care for drug-resistant tuberculosis patients in Nigeria
por: Bada, Florence O., et al.
Publicado: (2019)

Measuring Stigma to Assess the Social Justice Implications of Health-Related Policy Decisions: Application to Novel Treatment Regimens for Multidrug-Resistant Tuberculosis
por: Dowdy, David W., et al.
Publicado: (2020)

Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness
por: Nsengiyumva, Ntwali Placide, et al.
Publicado: (2022)

Cost of TB services: approach and summary findings of a multi-country study (Value TB)
por: Sweeney, S., et al.
Publicado: (2022)

Cost-Effectiveness of Automated Digital Microscopy for Diagnosis of Active Tuberculosis
por: Jha, Swati, et al.
Publicado: (2016)

Serological Testing Versus Other Strategies for Diagnosis of Active Tuberculosis in India: A Cost-Effectiveness Analysis
por: Dowdy, David W., et al.
Publicado: (2011)

Cost of TB services in the public and private sectors in Georgia
por: Chikovani, I., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tapvl5aob65ftul2vs86c8ahah